Implementation of HybridArc treatment technique in preoperative radiotherapy of rectal cancer: dose patterns in target lesions and organs at risk as compared to helical Tomotherapy and RapidArc by Thierry Gevaert et al.
Gevaert et al. Radiation Oncology 2012, 7:120
http://www.ro-journal.com/content/7/1/120RESEARCH Open AccessImplementation of HybridArc treatment
technique in preoperative radiotherapy of rectal
cancer: dose patterns in target lesions and organs
at risk as compared to helical Tomotherapy
and RapidArc
Thierry Gevaert1*, Benedikt Engels1, Cristina Garibaldi2, Dirk Verellen1, Peter Deconinck1, Michael Duchateau1,
Truus Reynders1, Koen Tournel1 and Mark De Ridder1Abstract
Purpose: HybridArc is a novel treatment technique blending aperture-enhanced optimized arcs with discrete IMRT-
elements, allowing selection of arcs with a set of static IMRT-beams. This study compared this new technique to
helical Tomotherapy, and RapidArc, in preoperative radiotherapy of rectal cancer.
Material and methods: Twelve rectal cancer patients treated consecutively with Tomotherapy Hi-Art II system
were simulated with HybridArc and RapidArc. Treatment plans were designed to deliver homogeneous dose of
46.0Gy to mesorectum and draining lymph nodes, with a simultaneous-integrated-boost to the primary tumor up
to a total dose of 55.2Gy. Planning objectives were 95% of prescribed dose to 95% of PTVs, while minimizing the
volume of small bowel receiving more than 15Gy (V15) and the mean bladder dose. Dose gradient towards
simultaneous-integrated-boost (GI), calculated by dividing the volume receiving more then 52.4Gy (95% of
PTV55.2Gy)to the volume of PTV55.2Gy, was kept below 1.5. Mean beam-on time and amount of MUs were also
analyzed.
Results: PTV swere adequately covered by all plans. Significant advantage was found for Tomotherapy in sparing
small bowel (V15 = 112.7cm3SD73.4cm3) compared to RapidArc (133.4cm3SD75.3cm3) and HybridArc
(143.7cm3SD74.4cm3) (p< 0.01). The mean bladder dose was better with RapidArc (20.6GySD2.2Gy) compared to
HybridArc (24.2Gy SD4.3Gy) and Tomotherapy (23.0GySD4.7Gy) (p< 0.01). The mean beam-on time was significantly
lower (p< 0.01) for HybridArc (2.7min SD0.8) and RapidArc (2.5min SD0.5) compared to Tomotherapy (11.0min
SD0.7). The total amount of MUs was significantly (p< 0.01) lower for RapidArc (547SD44)compared to HybridArc
(949 SD153).
Conclusions: HybridArc is a feasible solution for preoperative RT with a simultaneous-integrated-boost in rectal
cancer patients. It achieved similar PTV coverage with significant lower beam-on time, but less efficient in sparing
small bowel and bladder compared to Tomotherapy and RapidArc. The added value of HybridArc is that the
treatment modality can be implemented on every LINAC equipped with Dynamic-Conform-Arc and IMRT treatment
techniques, while maintaining the same QA-schemes.
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In patients with locally advanced rectal cancer, preopera-
tive (chemo) radiotherapy (RT) is considered standard of
care by improving local tumor control and overall sur-
vival [1-4]. The German Rectal Cancer Study Group
reported any grade 3 acute and late toxicity in 27%
and 14% of the patients undergoing conventional RT,
respectively [5]. The relative large horseshoe-shaped
planning target volume (PTV), with the bladder and
small bowel lying in the middle, justifies the use of
intensity-modulated RT (IMRT). Previous studies in our
department demonstrated the advantages of IMRT and
image-guided RT (IGRT) by helical Tomotherapy, regard-
ing accurate dose delivery, minimization of the setup mar-
gin, normal tissue sparing and toxicity [6-8].
Intensity-modulated arc therapy (IMAT), as described
by Yu [9], uses multiple treatment arcs with continuous
modulation of the shape of the treatment fields by a
multileaf collimator (MLC). RapidArc is a Volumetric
modulated arc therapy (VMAT) delivery technique and
hence an evolution of the IMAT concept. The treatment
is delivered in arc rotation during which the MLCs are
moving dynamically while the dose rate and gantry
speed are also varying [10,11]. HybridArc is novel treat-
ment technique and a different interpretation of the
IMAT concept, blending aperture-enhanced optimized
arcs with discrete IMRT-elements. This method allows se-
lection of Aperture-optimized-Arcs, delivered with con-
stant gantry speed and dose rate, with a set of static
IMRT-elements at specified intervals along each arc. By
weighting the contribution of arcs versus IMRT-elements,
HybridArc aims achieving an optimal dose distribution,
while limiting the use of IMRT.
Since HybridArc should provide a new approach of
IMRT and IMAT, it is critical to assess its performance
on a theoretical basis before clinical implementation. Be-
cause of the clinical meaningfulness of using IMRT in
preoperative RT of rectal cancer, this study was designed
to evaluate this new treatment technique in the neo-
adjuvant setting of rectal cancer patients and to compare
HybridArc to RapidArc and helical Tomotherapy.
Material and methods
Patient and treatment characteristics
For this study, we selected 12 consecutive patients with
stage II/III rectal cancer treated preoperatively in our
department in a phase II study with the Tomotherapy
Hi-Art II system (Tomotherapy Inc., Madison, WI).
According the protocol, all patients received a dose of
46.0Gy, in daily fractions of 2.0Gy, to the mesorectum and
draining lymph nodes. Patients with a circumferential
resection margin (CRM) of less than 2 mm on magnetic
resonance imaging (MRI) received a simultaneous-
integrated-boost to the primary tumor of 0.4Gy/day.Delineation of the CTV and OARs, CTV-PTV margins
and values of planning parameters for helical Tomother-
apy were previously extensively described [6]. Briefly,
the planning goals were delivering at least 95% of the pre-
scription dose to 95% of the PTV46.0Gy and PTV55.2Gy,
while keeping the normalization to the mean dose of
both PTVs and the irradiated volume of small bowel
and mean bladder dose as low as possible. As the vol-
ume of small bowel receiving more than 15Gy (V15) is a
known significant volumetric factor for developing
grade 3+ acute small bowel toxicity [12], this parameter
was used for inverse planning [13]. The 12 patients were
simulated on the RapidArc treatment planning system
Eclipse v8.6 (Varian, Palo Alto, CA) and on the iPlan
v4.5 (Brainlab AG, Feldkirchen, Germany) treatment
planning system, where a preclinical version of a new
treatment modality HybridArc was installed.
HybridArc treatment modality
HybridArc is a technique, which automatically blends
the Aperture-optimized-Arcs with discrete IMRT tech-
nology. The arcs are inversely optimized Dynamic-
Conformal-Arcs (DCAs), where the MLC shapes can be
automatically modified to respect predefined objectives
for the PTV and OARs. The automatic aperture
optimization replaces elaborate and time-consuming
manual field shaping and generates consistent and user-
independent results. A classic DCA treatment employs
leaf adaptations during the arc movement, while keeping
the gantry speed and dose rate constant. The software
typically uses control points with a 10° gantry spread
step size, to determine a MLC planning shape specific to
the projection of the PTV in this beam direction. The
MLC leaves adapt to the different planning shapes con-
sidering the machine specific constraints of the MLC
leaf movements. The HybridArc aperture optimization
technique modifies classic DCA planning shapes to ful-
fill predefined PTV and OAR objectives. The aperture
optimization is similar to optimizing several co-planar
IMRT-elements: first beam fluences are optimized, and
then these fluences are transformed to leaf patterns.
During an aperture optimization, the classic dynamic
conformal beam shape of each control point is subdivided
into arc specific fluence beamlets. The optimization algo-
rithm determines, in considering all other control points,
the optimal fluence pattern for each single control point
to fulfill the desired constraints. Unlike IMRT fluence
patterns, the aperture optimization fluence uses only
two fluence beamlet levels: fully irradiated, and not
irradiated at all. The resulting control points fluence
pattern is used to generate its specific planning
shape.
The inverse planning engine for the aperture optimization
process uses a combination of a Maximum-Likelihood-
Figure 1 One Aperture optimized Arc with a gantry start/stop
of 200°-160° with 7 discrete IMRT elements equally distributed
over the arc.
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resulting in the Dynamically-Penalized-Likelihood al-
gorithm [14]. This algorithm has been introduced
successfully in iPlan’s static IMRT-beam optimization
and has been adapted for the aperture optimization
process.
In other words, the method can be considered as a
combination of forward planning (the number and pos-
ition of the arcs as well as the start and stop angles, and
the number of IMRT-elements are user defined) and in-
verse planning to optimize the aperture of the MLC
from an anatomical shape of the target with or without
excluding the critical structures. This Aperture-
optimized-Arcs step is fully automated and can be
guided by various penalization parameters to achieve ap-
propriate OAR protection (dose optimization for OAR
sparing at the cost of PTV coverage) including MU effi-
ciency in the optimization process. After completion of
the Aperture-optimized-Arcs, the inverse planning con-
centrates on the intensities in the IMRT-elements by
moving the leaves continuously during each beam, to
boost up the PTV coverage and to achieve a volumetric
dose painting of the PTV within the provided dose con-
straints for the OAR. The user can adapt the weighting
between Aperture-optimized-Arcs and discrete IMRT-
elements prior to the optimization.HybridArc planning
HybridArc plans were generated for a Trilogy (Varian,
Palo Alto, CA) linear accelerator (Linac), which is
equipped with a dynamic high-resolution-MLC (Millen-
nium 120 leaves MLC) characterized by a spatial reso-
lution of 5 mm at isocenter for the central 20 cm and of
10 mm in the outer 20 cm). In this study, we used one
Aperture-optimized-Arcs with a gantry start/stop angle
of 200°-160° and 6-7 discrete IMRT-elements equally
distributed over the arc (Figure 1), with a weight of 60%
and 40% for Aperture-optimized-Arcs and IMRT, re-
spectively. The planning constraints for the Aperture-
optimized-Arcs were medium OAR sparing, which will
exclude half of the overlap volume of the OAR within
the PTV. Once the arc optimized, the IMRT-elements
will accomplish the PTV coverage and the horseshoe
shape of dose around the PTV to spare the OAR. When
the IMRT optimizations finished, the system shows
four possible treatment plans: PTV only, where the
optimization will only focus on the PTV coverage, and
three OAR sparing optimization going from low OAR
sparing until high, where the priority is given to the
OAR. Depending on the results, one of this
optimization was chosen. The objectives for target
volumes and OARs were similar to the existing plans
on helical Tomotherapy.RapidArc planning
RapidArc plans were also generated with the Trilogy
(Varian, Palo Alto, CA) Linac equipped with the same
high-resolution MLC model (Millennium 120 leaves
MLC) as the one for the HybridArc plans. RapidArc
plans consisted of two 358° arcs of 6 MV photon beam.
To minimize the contribution of the tongue and groove
effect during the arc rotation the collimator was rotated
to ±20°. A RapidArc plan consists of optimizing a dose
distribution from dose-volume objectives. Planning
objectives were transferred into numerical dose-volume
constraints used in the optimization phase and tailored
to the specific patient characteristics. Priorities were
adjusted during optimization to achieve the best results
for each patient.
To achieve the required level of modulation, the opti-
miser is enabling to continuously vary the dose rate,
MLC leaf positions and the gantry rotational speed.
Plans were optimized selecting a maximum dose rate of
600 MU/min.
Tomotherapy planning
Tomotherapy plans were generated using a fan beam
thickness (FBT) of 2.5 cm. This choice was made be-
cause the larger available FBT of 5 cm resulted in a too-
large penumbra in the cranio-caudal direction, resulting
in more healthy tissue irradiated. Using the smaller
available FBT of 1 cm resulted in an increase average
overall treatment compared to the FBT of 2.5 cm. Pitch
ranged from 0.287 to 0.31, depending on the level of dif-
ficulty to achieve the OAR constraints. Modulation fac-
tor varied from 2 to 3, depending on homogeneity and
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ical dose-volume constraints were used to optimize the
plans to the specific patient characteristics. Priorities
and dose penalties were adjusted during optimization to
achieve the best results for each patient.
Treatment planning evaluation
Several parameters of the dose volume histograms were
computed to make the comparison between the different
systems. For the PTV, the mean target dose and the vol-
ume receiving 95% of prescription dose were analyzed.
Furthermore, the dose gradient towards the boost region
(GI), defined as the ratio of the volume receiving more
than 52.5Gy to the volume of the PTV55.2Gy, was ana-
lyzed. In concordance with the planning objectives on
helical Tomotherapy, we tried to keep the GI in the
HybridArc and RapidArc plans below 1.5. For the OAR,
the mean dose and V15 for the small bowel and the
mean dose for the bladder were analyzed. A comparison
of delivery efficiency, such as beam-on time among the
different treatment modalities was also conducted. As
MUs cannot be compared in any meaningful way with
helical Tomotherapy (fan-beam versus cone-beam), the
MUs were only compared for the HybridArc and Rapi-
dArc plans. All the planning results were compared by a
paired two-sided t test.
Results
Figure 2 shows the average DVHs for the PTV46.0Gy,
PTV55.2Gy, small bowel and bladder. The mean PTV vol-
ume was 1653.3cm3 (SD 225.0cm3) with a mean
simultaneous-integrated-boost volume of 131.9cm3
(SD 95.8cm3). All treatment plans were able to achieve
the constraints placed on PTV coverage. The mean
doses to the PTV46.0Gy and PTV55.2Gy were 46.6Gy
(SD 0.5Gy) and 56.2Gy (SD 0.4Gy) for HybridArc,Figure 2 The average DVHs for the PTV46.0Gy, PTV55.2Gy, small bow
line) and Helical Tomotherapy (straight-line), respectively.47.5Gy (SD 0.4Gy) and 56.5Gy (SD 0.3Gy) for Rapi-
dArc and 46.7Gy (SD 0.4Gy) and 56.1Gy (SD 0.4Gy)
for helical Tomotherapy, respectively. The V43.7
(95% of 46.0Gy) and V52.4 (95% of 55.2Gy)
were95.6% (SD 0.8%) and 99.1% (SD 0.5%) for Hybri-
dArc, 97.8% (SD 0.9%) and 99.3% (SD 0.5%) for Rapi-
dArc, and 96.5% (SD 1.7%) and 99.6% (SD 0.4%) for
helical Tomotherapy, respectively. The dose gradients
between the PTV46.0Gy and the PTV55.2Gy were
steep for the different treatment modalities (p< 0.01)
with a GI of 1.31 (SD 0.16), 1.28 (SD 0.10) and 1.33
(SD 0.16) for HybridArc, RapidArc and helical
Tomotherapy, respectively. Typical dose distributions
for HybridArc for one patient are shown in Figure 3
for an axial view.
Concerning the OARs, a significant advantage was
found for helical Tomotherapy in sparing the small
bowel (V15) compared to other solutions (HybridArc
and RapidArc) (p< 0.01). The mean bladder dose was
better spared RapidArc (p< 0.01). The mean small
bowel dose was 11.5Gy (SD 3.9Gy), 11.3Gy (SD 3.8Gy)
and 11.7Gy (SD 3.0Gy) for HybridArc, RapidArc and
helical Tomotherapy, respectively. The V15 for the
small bowel was 143.7cm3 (SD 74.4cm3), 133.4cm3
(SD 75.3cm3) and 112.7cm3 (SD 73.4cm3) for Hybri-
dArc, RapidArc and helical Tomotherapy, respectively.
The wide SD for V15 of the small bowel is caused by
the variability of the volume small bowel lying in the
pelvis of the different patients. The mean bladder
dose was 24.2Gy (SD 4.3Gy),20.6Gy (SD 2.2Gy) and
23.0Gy (SD 4.7Gy) for HybridArc, RapidArc and helical
Tomotherapy, respectively.
For the treatment delivery efficiency, the mean beam-
on time was significantly lower (p< 0.01) for HybridArc
(2.7min SD 0.8) and RapidArc (2.5min SD 0.5) com-
pared tohelical Tomotherapy (11.0min SD 0.7). The totalel and bladder, for HybridArc (dashed-line), RapidArc (dotted-
Figure 3 Axial view of typical dose distributions for HybridArc.
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HybridArc (949SD 153) system compared to RapidArc
(547 SD 44) system.
Discussion
IMRT is mainly used to generate concave dose distribu-
tions, which are needed in the preoperative RT of rectal
cancer to minimize the irradiated volume of small bowel
and bladder. Especially, relative large PTVs enveloped by
OAR such as those presented in rectal cancer have been
proven to be challenging [15]. Techniques such as step
and shoot IMRT, VMAT and helical Tomotherapy are
able to create conformal isodoses with a reduction of the
irradiated nearby healthy tissues [6,15]. Engels et al. [7]
initially performed a dosimetric study comparing stand-
ard 3D-CRT with IMRT and showed a significant lower
V15 of the small bowel and its NTCP for IMRT, while
maintaining an adequate PTV coverage for the preopera-
tive treatment of rectal cancer.
Moreover, IMRT allows dose escalation to the primary
tumor without increased normal tissue toxicity with the
simultaneous-integrated-boost strategy. Previous studies in
our department explored this strategy in preoperative RT
of rectal cancer by the use of helical Tomotherapy[6-8] dis-
playing a favorable acute toxicity profile and no increased
toxicity with the administration of a simultaneous-
integrated-boost [6]. Differences in the characteristics of
these IMRT techniques might lead to differences in target
conformity, organ sparing (avoidance of toxicities to small
bowel and bladder in rectal cancer patients treated with
RT preoperatively), and treatment quality and efficiency.
Whenever a new treatment technique is introduced, it
should be evaluated against well-established technolo-
gies. In the present planning study, we evaluated the
feasibility of this novel treatment technique, HybridArc,
for preoperative RT of rectal cancer and compared the
planning results with respect to dosimetric parameters
and the treatment efficiency to the helical Tomotherapydedicated IMRT system, a technique in which we build
up a wide expertise over the last years, and to RapidArc,
a well-established VMAT solution used at the European
Institute of Oncology (EIO) hospital in Milan. This plan-
ning study is to our knowledge the first evaluation of
HybridArc, a novel automated direct-aperture optimized
arc with equally distributed integrated IMRT-elements
and demonstrated that HybridArc could achieve similar
target coverage to well-established rotational IMRT
solutions.
The GI showed a steep dose gradient between the
simultaneous-integrated-boost and the PTV for the dif-
ferent planning systems. The OARs, more specifically
for the V15 of the small bowel and the mean bladder
dose, were less spared with HybridArc.
Several drawbacks of these techniques should be
addressed. The complex process of treatment planning
and treatment delivery requires extensive physics quality
assurance [16]. Due to the completely dynamic implemen-
tation and new method of operating the Linac (dose rate
and gantry speed changement during arc delivery), correct
treatment delivery of VMAT must be extensively verified
for both machine general specific performance and treat-
ment plans [17]. The same has to be performed for helical
Tomotherapy, due to its helical way of delivering dose and
fan-beam irradiation. Therefore, for these treatment mo-
dalities, new Quality-Assurance (QA) schemes have to be
elaborated. HybridArc starts from two well-known treat-
ment modalities (DCA and Dynamic-MLC-IMRT
(DMLC-IMRT)) and redesigned them at software base.
The concept of decoupling the rotational delivery part
(DCA) and IMRT-part place less burden on the mechan-
ical constraints of the treatment machine. Because of this,
there is no need to execute other specific performance on
the LINAC and same dedicated QA schemes for DCA
and DMLC-IMRT can be maintained to verify the treat-
ment delivery. This study focused on comparing this new
IMAT concept with a well known rotational IMRT con-
cept (Tomotherapy) and a VMAT concept (RapidArc).
Pre-treatment QA was beyond the scope of this study. Al-
though, we can already anticipate as Petoukhova et al.
[18] already evaluate the dosimetric accuracy for various
treatment sites and found a good agreement for the
HybridArc plans.
The prolonged beam delivery time of IMRT compared
to 3D-CRT may worsen the accuracy of treatment due to
increased intra-fractional patient motion [19]. Beam-on
time of HybridArc is comparable to RapidArc, significantly
lower as compared to helical Tomotherapy, which means
faster treatment delivery without sacrificing quality of the
plans. Moreover, as IGRT is used, treatments occurring in
a shorter time after imaging may minimize the likelihood
that treatment volumes stay beyond their respective treat-
ment margins.
Gevaert et al. Radiation Oncology 2012, 7:120 Page 6 of 7
http://www.ro-journal.com/content/7/1/120Another issue of concern is the increased number of
MUs required in IMRT treatment, which leads to greater
interleaf scatter dose hypothesizing an increase in sec-
ondary malignancy induction [20]. Our data showed that
HybridArc plans require 53% more MUs than RapidArc
plans. The reason of this finding is that beside the single
Aperture-optimized-Arcs, there are also 6 static IMRT
elements, which require a large number of MUs.
Moreover, the risk of developing a second malignancy
after RT is not only hypothesized on the scatter dose
and MUs, but also on the volume of normal tissue re-
ceiving low-dose RT [20]. The improved OAR sparing
and PTV coverage is achieved at the price of increased
low dose exposure of the surrounding healthy tissue.
helical Tomotherapy delivers dose circumferentially
around the patient, potentially leading to an increase in
the volume on normal tissues exposed to low doses, the
effects of which are not well understood. Figure 2
showed that for HybridArc and RapidArc the low-dose
wash to the OAR will be less compared to helical
Tomotherapy.Conclusion
Although additional studies are needed to evaluate
HybridArc for other anatomical sites, treatment plan
QA and clinical outcome after HybridArc, this planning
study demonstrated that HybridArc is a feasible tech-
nique for preoperative irradiation of rectal cancer
patients. It was able to achieve a homogeneous PTV
coverage in the simultaneous-integrated-boost scenario,
while limiting the irradiated volume of OARs and keep-
ing the beam-on time comparable to RapidArc and sig-
nificantly lower than helical Tomotherapy. Compared to
our standard in IMRT for rectal cancer, helical
Tomotherapy, and a VMAT solution (RapidArc), Hybri-
dArc achieved similar PTV coverage, whereas it
appeared to be less impressive in sparing the small
bowel and bladder. The added value of HybridArc is that
the treatment modality can be implemented on a LINAC
that can neither change dose rate nor gantry speed during
delivery of arcs. The only condition is that the LINAC is
equipped with DCA and IMRT treatment techniques.By
avoiding conflicting the mechanical constraints of the de-
livery system, the same LINAC performance and QA
schemes for DCA and IMRT can be maintained.Competing interests
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